After the London tragedy, is it still possible to consider Phase I is safe?
Sibille
Michel
M
Donazzolo
Yves
Y
Lecoz
Franck
F
Krupka
Emmanuel
E
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D017321:Clinical Trials, Phase I as Topic / Q000401:mortality*; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects* / Q000494:pharmacology; D018570:Risk Assessment
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; C509303:TGN-1412